Kappadath Laboratory
S. Cheenu Kappadath, Ph.D. DABR, DABSNM, FAAPM
Principal Investigator
Imaging Physics
Professor
We are adapting novel nuclear and PET imaging technologies into advanced clinical applications.
Our research is focused on advancing imaging and diagnosis with clinical nuclear medicine (CNM), positron emission tomography (PET), single photon emission tomography (SPECT), and x-ray computed tomography (CT) by applying physics, engineering, and mathematics to improve the quantitative accuracy.
We aim to improve clinical image quality through innovations in data acquisition and image generation. We adapt novel nuclear medicine technologies and incorporate advanced computational techniques to aid clinicians in their diagnosis and patient-specific radionuclide treatment planning.
We are actively working on the following research topics.
Current Grant Funding
Co-Investigator, TriNav Infusion System for the Evaluation of Fidelity between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning, Principal Investigator: Armeen Mahvash MD, TriSalus Medical, 1/1/2023-12/31/2023
Co-Investigator, Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients with Colorectal Liver Metastases, NCT05195710, Principal Investigator: Ching-Wei Tzang MD, Sirtex Medical, 10/1/2022-12/31/2024
Principal Investigator, Evaluation of novel MBI tumor uptake metric, SUVb, for predicting tumor response in breast cancer patients, Co-Principal Investigator: Maia Rauch MD PhDMD Anderson QIAC, 5/1/2022-4/30/2023
Principal Investigator: A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90), NCT04736121, Sirtex Medical, 1/1/2021-12/31/2023
Co-Principal Investigator: Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D), NCT03896646, Boston Scientific BTG, 10/1/2019-9/30/2023
Principal Investigator: Evaluation of the distribution of radiopaque non-radioactive (EYE90) 90Y-radioembolic microsphere in liver and kidneys in a swine model, ABK Biomedical, 2/1/2020-1/31/2023
Completed Grant Funding
Principal Investigator: Establish the minimum detectable PET activity concentrations when imaging F-18 and Ga-68 labeled prostate cancer radiotracers with the GE Signa PET/MR, MD Anderson, 3/15/2020-3/14/2021
Principal Investigator: A TheraSphere Advanced Dosimetry Retrospective Global Evaluation in Hepatocellular Carcinoma Treatment (TARGET), NCT03295006, BTG International Inc, 1/1/2017-12/31/2019
Co-Principal Investigator: Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment, NCT03028311, 13015485-V101, Principal Investigator: Armeen Mahvash M.D., SIRTEX Medical Limited,6/25/2016-6/30/2019
Principal Investigator: Quantitative 99mTc-Sestamibi Molecular Breast Imaging (MBI) using GE Discovery NM750b, GE-CABI, General Electric, 9/1/2015-9/1/2019
Principal Investigator: Quantitative 90Y PET/CT: Quest Site Assessment Study, SIRTEX Medical Limited, 2/2/2014-5/31/2019
Principal Investigator: A novel dose calculation method for targeted radionuclide therapy, R01-CA13896-02, (Sub-award No. 601889), Christiana Care Health Services/NIH, 8/1/2012-7/31/2016